ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, the lower BCR/ABL1 transcript levels in peripheral blood of 86 first-line dasatinib-treated CML patients after 12 months were associated with the absence of three inhibitory KIRs and a similar trend was visible for two activating KIRs including KIR2DS1 (Kreutzman et al., 2012).